Letter from the Editor EditorDr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch ConferenceWCLC 2019 8 November 2019 23:30
Five-fold increase of OS at 5 years with nivolumab vs docetaxel Presented ByProf. Scott Gettinger, Yale Cancer Center, USA TrialCheckMate 017, CheckMate 057 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:00
Tumour mutation score is a better predictor than TMB ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:42
New technologies in lung cancer detection ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 22:50
Five-fold increase of OS at 5 years with nivolumab vs docetaxel Presented ByProf. Scott Gettinger, Yale Cancer Center, USA TrialCheckMate 017, CheckMate 057 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:00
Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression TrialKEYNOTE-021, KEYNOTE-189, KEYNOTE 407 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 22:57
pTMB is a feasible predictive biomarker for chemoimmunotherapy ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 21:58
Promising phase 1 results of novel KRAS-inhibitor in NSCLC Presented ByDr Ramaswamy Govindan, Washington University School of Medicine, USA ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 20:59
Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer Presented ByDr Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA TrialLIBRETTO-001 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 19:01
High need for biomarkers for stage III lung cancer ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 18:03
CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 17:05
Durvalumab added to etoposide improves outcomes in ES-SCLC TrialCASPIAN ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:06
Talazoparib + low-dose temozolomide seems promising in ES-SCLC ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 22:08
New targets in thymic epithelial tumours may aid in identifying treatment options ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 21:10
Novel targets in mesothelioma may aid in developing treatment strategies TrialPhase 2, ADAM ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 09:11
BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:14
Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities Presented ByDr Fabrice Barlesi, Hôpitaux de Marseille, France TrialPhase 4, CHECKMATE-817 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 21:15
Tackling immunotherapy resistance ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 09:17
Older age and low neutrophilia inflammation predictor for osimertinib efficacy ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:19
EGFR TKI retreatment effective after earlier discontinuation ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 09:20
First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression Presented ByDr Martin Reck, Lung Clinic Grosshansdorf, Germany TrialKEYNOTE-024 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 23:23
Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC TrialPhase 3, IMpower 131 ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 21:25
Less focus on quality of life in recent phase 3 trials ConferenceWCLC 2019 TypePeer-reviewed article 8 November 2019 09:26